Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Non-Current Assets (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Other Non-Current Assets for 7 consecutive years, with $20.3 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 18.49% to $20.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.3 million through Dec 2025, up 18.49% year-over-year, with the annual reading at $20.3 million for FY2025, 18.49% up from the prior year.
  • Other Non-Current Assets hit $20.3 million in Q4 2025 for Immunocore Holdings, up from $16.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $20.3 million in Q4 2025 to a low of $6.7 million in Q4 2021.
  • Historically, Other Non-Current Assets has averaged $15.2 million across 5 years, with a median of $16.5 million in 2025.
  • Biggest five-year swings in Other Non-Current Assets: soared 68.06% in 2023 and later decreased 4.35% in 2025.
  • Year by year, Other Non-Current Assets stood at $6.7 million in 2021, then increased by 29.45% to $8.6 million in 2022, then skyrocketed by 68.06% to $14.5 million in 2023, then grew by 18.27% to $17.1 million in 2024, then increased by 18.49% to $20.3 million in 2025.
  • Business Quant data shows Other Non-Current Assets for IMCR at $20.3 million in Q4 2025, $16.5 million in Q3 2025, and $17.0 million in Q2 2025.